3 completed, 2 withdrawn. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Withdrawn 2 |
| Phase 2 | 5 | Completed 3, Withdrawn 2 |
Follow retrovector encoding mutant anti-cyclin G1: new trials by email Literature Review of retrovector encoding mutant anti-cyclin G1 trials Research Report on retrovector encoding mutant anti-cyclin G1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 DeltaRex-G - COVID-19, Cytokine Storm | Phase 1 / Phase 2 | Withdrawn | Aveni Foundation | 2022-12-12 | 2025-02-24 | |
| Safety and Efficacy Study Using Rexin-G for Sarcoma Rexin-G - Sarcoma | Phase 1 / Phase 2 | Completed | Epeius Biotechnologies | 36 | 2007-07-01 | 2011-06-10 |
| Safety and Efficacy Study Using Rexin-G for Breast Cancer Rexin-G - Breast Cancer | Phase 1 / Phase 2 | Completed | Epeius Biotechnologies | 20 | 2007-07-01 | 2011-06-10 |
| Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer Rexin-G - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Epeius Biotechnologies | 20 | 2007-07-01 | 2011-06-10 |
| Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver Mx-dnG1 Retroviral Vector - Colorectal Neoplasms | Phase 1 / Phase 2 | Withdrawn | University of Southern California | 2002-11-01 | 2014-05-22 |
Breast Neoplasms (1) · COVID-19 (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Cytokine Release Syndrome (1) · Pancreatic Neoplasms (1) · Respiratory Distress Syndrome (1) · Sarcoma (1)
Epeius Biotechnologies (3) · Aveni Foundation (1) · University of Southern California (1)
United States (3)
Sant P Chawla, M.D. (3) · Howard W Bruckner, M.D. (2) · Sant P Chawla, MD (1)